Skip to main content
. Author manuscript; available in PMC: 2013 Aug 7.
Published in final edited form as: Biochemistry. 2012 Jul 25;51(31):6220–6227. doi: 10.1021/bi300619a

Figure 6.

Figure 6

FPLC of Superdex-200 elution profiles of apoLp-III incubations with LPS. Panel A–H: apoLp-III incubated with D-LPS (at a constant protein-LPS mass ratio of 1:5) at the following protein concentrations: 0.05 mg/mL (A), 0.1 mg/mL (B), 0.2 mg/mL (C), 0.3 mg/mL (D), and 0.5 mg/mL (E). Solid line: apoLp-III only; dotted line: LPS only, dashed line: apoLp-III in the presence of LPS. Panel F: apoLp-III (0.5 mg/mL) in the presence of heparin (2.5 mg/mL). Panels G and H: apoLp-III in the presence of LPS at a 1:5 mass ratio using a protein concentration of 0.05 mg/mL (G), and 0.5 mg/mL (H).